Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ultrasound may spot arthritis Flare-Ups before symptoms start

NCT ID NCT01765374

Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether ultrasound could detect signs of rheumatoid arthritis (RA) relapse before symptoms appear in patients treated with rituximab. Thirty adults with RA who had not responded to at least one TNF-blocking drug were included. Researchers used ultrasound to measure joint inflammation over time, aiming to catch relapses earlier than standard clinical checks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rituximab
What this could lead to
If successful, this approach could help doctors detect rheumatoid arthritis flare-ups earlier, allowing for timely treatment adjustments.
What could go wrong
This is a small, completed Phase 4 study with only 30 participants, so results may not apply to everyone. Ultrasound detection may not reliably predict clinical symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

30 people

The number who actually took part.

Start date

Feb 2011

Finished

Oct 2014

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * failure to at least one TNF-blocking agent Exclusion Criteria: * pregnant or childbearing woman * Rituximab contraindication * woman unable to use contraceptive means

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • Department of Rheumatology

    Le Havre, 76290, France

  • Department of Rheumatology CHG Elbeuf

    Saint-Aubin-lès-Elbeuf, 76410, France

  • Department of Rheumatology, CHU de Caen

    Caen, 14033, France

  • Department of rheumatology

    Rouen, 76031, France

  • Normandy

    Caen, Le Havre, Rouen, Elbeuf, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.